The Liberty SiriusXM Group (LSXMK)
USD 22.29
(-1.15%)
USD 22.29
(-1.15%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.82 Billion | 1.95 Billion | 1.89 Billion | 1.92 Billion | 1.94 Billion | 1.78 Billion |
| Net Income | 829 Million | 1.5 Billion | 875 Million | -719 Million | 735 Million | 1 Billion |
| Depreciation & Amortization | 624 Million | 611 Million | 603 Million | 573 Million | 537 Million | 369 Million |
| Deferred income taxes | 36 Million | 420 Million | -3 Million | 45 Million | 247 Million | 253 Million |
| Stock-based compensation | 203 Million | 209 Million | 215 Million | 234 Million | 267 Million | 156 Million |
| Change in working capital | -181 Million | -247 Million | -314 Million | -147 Million | 28 Million | 17 Million |
| Other non-cash items | 315 Million | -536 Million | 518 Million | 1.93 Billion | 130 Million | -14 Million |
| Investing Cash Flow | -696 Million | -493 Million | -64 Million | -734 Million | 384 Million | -756 Million |
| Investments in PPE | -650 Million | -426 Million | -388 Million | -350 Million | -363 Million | -356 Million |
| Acquisitions | -50 Million | -136 Million | -86 Million | -396 Million | 294 Million | -405 Million |
| Investment purchases | -50 Million | -58 Million | 388 Million | -96 Million | 363 Million | -405 Million |
| Sales/Maturities of investments | 50 Million | 66 Million | 177 Million | 96 Million | 446 Million | 14 Million |
| Other Investing Activities | 4 Million | 61 Million | -155 Million | 12 Million | -356 Million | 5 Million |
| Financing Cash Flow | -1.18 Billion | -1.7 Billion | -2.23 Billion | -689 Million | -1.92 Billion | -1.55 Billion |
| Debt repayment | -1.1 Billion | -3.55 Billion | -5.87 Billion | -2.95 Billion | -4.83 Billion | -2.43 Billion |
| Dividends payments | -65 Million | -249 Million | -58 Million | -64 Million | -68 Million | -59 Million |
| Common Stock Repurchased | -274 Million | -1 Billion | -2.02 Billion | -1.8 Billion | -2.57 Billion | -1.78 Billion |
| Common Stock Issuance | - | - | 6.29 Billion | 754 Million | 5.79 Billion | 2.79 Billion |
| Other Financing Activities | 255 Million | 3.1 Billion | -573 Million | 3.37 Billion | -239 Million | -77 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | 21 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -181 Million | -247 Million | -314 Million | -147 Million | 28 Million | -4 Million |
| Cash at beginning of period | 362 Million | 606 Million | 1 Billion | 507 Million | 102 Million | 625 Million |
| Cash at end of period | 306 Million | 370 Million | 606 Million | 1 Billion | 507 Million | 102 Million |
| Capital Expenditure | -650 Million | -426 Million | -388 Million | -350 Million | -363 Million | -356 Million |
| Effect of forex changes on cash | -1 Million | -236 Million | -3 Million | 3 Million | - | - |
| Net cash flow / Change in cash | -56 Million | -236 Million | -402 Million | 501 Million | 405 Million | -523 Million |
| Free Cash Flow | 1.17 Billion | 1.53 Billion | 1.5 Billion | 1.57 Billion | 1.58 Billion | 1.42 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 299 Million | 241 Million | 229 Million | 829 Million | 365 Million | 217 Million |
| Depreciation & Amortization | 156 Million | 155 Million | 164 Million | 624 Million | 145 Million | 154 Million |
| Deferred income taxes | -7 Million | 17 Million | 78 Million | 36 Million | 82 Million | 15 Million |
| Stock-based compensation | 48 Million | 48 Million | 52 Million | 203 Million | 57 Million | 46 Million |
| Change in working capital | 30 Million | -199 Million | -50 Million | -181 Million | -84 Million | 64 Million |
| Other non-cash items | 62 Million | 24 Million | 55 Million | 315 Million | -121 Million | 39 Million |
| Investing Cash Flow | -196 Million | -354 Million | -131 Million | -696 Million | -188 Million | -135 Million |
| Investments in PPE | -173 Million | -174 Million | -130 Million | -650 Million | -186 Million | -129 Million |
| Acquisitions | -23 Million | -179 Million | -6 Million | -50 Million | -2 Million | -3 Million |
| Investment purchases | -23 Million | -180 Million | 174 Million | -50 Million | -2 Million | -3 Million |
| Sales/Maturities of investments | - | - | -7 Million | 50 Million | 4 Million | 3 Million |
| Other Investing Activities | 23 Million | -1 Million | 5 Million | 4 Million | -2 Million | -3 Million |
| Financing Cash Flow | -241 Million | -73 Million | -417 Million | -1.18 Billion | -240 Million | -519 Million |
| Debt repayment | -216 Million | -37 Million | -669 Million | -1.1 Billion | -119 Million | -159 Million |
| Dividends payments | -34 Million | -17 Million | -17 Million | -65 Million | -15 Million | -16 Million |
| Common Stock Repurchased | -6 Million | -17 Million | -12 Million | -274 Million | -75 Million | -137 Million |
| Common Stock Issuance | - | - | -1.19 Billion | - | - | - |
| Other Financing Activities | 9 Million | -36 Million | 269 Million | 255 Million | -31 Million | -207 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 30 Million | -199 Million | -50 Million | -181 Million | -84 Million | 64 Million |
| Cash at beginning of period | 135 Million | 315 Million | 335 Million | 362 Million | 319 Million | 438 Million |
| Cash at end of period | 188 Million | 152 Million | 315 Million | 306 Million | 335 Million | 319 Million |
| Capital Expenditure | -173 Million | -174 Million | -130 Million | -650 Million | -186 Million | -129 Million |
| Effect of forex changes on cash | - | - | 97 Million | -1 Million | -99 Million | - |
| Net cash flow / Change in cash | 53 Million | -163 Million | -20 Million | -56 Million | 16 Million | -119 Million |
| Free Cash Flow | 415 Million | 90 Million | 398 Million | 1.17 Billion | 258 Million | 406 Million |
INDOTECH
STLN
REVBW
DOSE
2065
9850